1. Home
  2. Analysis
  3. Sinemet-cr
  4. Nuplazid

Sinemet cr and Nuplazid drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Sinemet cr (carbidopa; levodopa) and Nuplazid (pimavanserin tartrate). Common drug interactions include fatigue among females and hallucination among males.

The phase IV clinical study analyzes what interactions people have when they take Sinemet cr and Nuplazid. It is created by eHealthMe based on reports of 83 people who take the same drugs from the FDA, and is updated regularly.

What is Sinemet cr?

Sinemet cr has active ingredients of carbidopa; levodopa. It is often used in parkinson's disease. eHealthMe is studying from 2,852 Sinemet cr users. Check the latest studies of Sinemet cr.

What is Nuplazid?

Nuplazid has active ingredients of pimavanserin tartrate. eHealthMe is studying from 47,103 Nuplazid users. Check the latest studies of Nuplazid.

On Jul, 20, 2026

83 people who take Sinemet cr and Nuplazid together, and have interactions are studied.

Sinemet cr and Nuplazid drug interactions.

What are the common drug interactions of Sinemet Cr and Nuplazid, by gender? *:

female:

  1. Fatigue (feeling of tiredness)
  2. Confusional state
  3. Gait disturbance
  4. Drug ineffective
  5. Tremor (trembling or shaking movements in one or more parts of your body)
  6. Malaise (a feeling of general discomfort or uneasiness)
  7. Anxiety
  8. Agitation (state of anxiety or nervous excitement)
  9. Death
  10. Fall

male:

  1. Hallucination (an experience involving the perception of something not present)
  2. Death
  3. Abnormal behaviour
  4. Bradycardia (abnormally slow heart action)
  5. Constipation
  6. Dysphagia (a condition in which swallowing is difficult or painful)
  7. Contusion (a type of hematoma of tissue in which capillaries)
  8. Hallucinations, mixed (sensations that appear real but are created by your mind -mixed)
  9. Herpes zoster
  10. Overdose

What are the common drug interactions of Sinemet Cr and Nuplazid, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

  1. Abdominal distension
  2. Bruxism (habitual grinding of the teeth, typically during sleep)
  3. Urinary tract infection
  4. Weight decreased

60+:

  1. Constipation
  2. Urinary tract infection
  3. Fall
  4. Mobility decreased (ability to move is reduced)
  5. Delusion (a false belief or opinion)
  6. Gait disturbance
  7. Somnolence (a state of near-sleep, a strong desire for sleep)
  8. Dizziness postural
  9. Abnormal behaviour
  10. Anger

What are the existing conditions these people have? *

  1. Hallucinations (sensations that appear real but are created by your mind): 37 people, 44.58%
  2. Delusion (a false belief or opinion): 27 people, 32.53%
  3. Pain: 7 people, 8.43%
  4. Psychotic Disorder: 6 people, 7.23%

* Approximation only. Some reports may have incomplete information.

Do you take Sinemet cr and Nuplazid?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Sinemet cr and Nuplazid:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Sinemet cr:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Nuplazid:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Sinemet cr and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Nuplazid and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on carbidopa; levodopa and pimavanserin tartrate (the active ingredients of Sinemet cr and Nuplazid, respectively), and Sinemet cr and Nuplazid (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.